John Bolodeoku

1.6k total citations
57 papers, 1.3k citations indexed

About

John Bolodeoku is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, John Bolodeoku has authored 57 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Oncology and 11 papers in Epidemiology. Recurrent topics in John Bolodeoku's work include Urinary Bladder and Prostate Research (8 papers), Urinary Tract Infections Management (8 papers) and Pelvic floor disorders treatments (7 papers). John Bolodeoku is often cited by papers focused on Urinary Bladder and Prostate Research (8 papers), Urinary Tract Infections Management (8 papers) and Pelvic floor disorders treatments (7 papers). John Bolodeoku collaborates with scholars based in United Kingdom, Netherlands and United States. John Bolodeoku's co-authors include Kazuhiro Yoshida, Takashi Sugino, Ted Drogendijk, Christopher R. Chapple, D.M. Wright, David G. Jackson, Philip Toozs‐Hobson, Luigi Selvaggi, R. Martínez-García and Steve Goodison and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Cancer.

In The Last Decade

John Bolodeoku

47 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Bolodeoku United Kingdom 15 642 556 441 266 247 57 1.3k
Travis J. Jerde United States 18 364 0.6× 93 0.2× 90 0.2× 237 0.9× 46 0.2× 49 894
Ying-hao SUN China 18 203 0.3× 157 0.3× 114 0.3× 335 1.3× 24 0.1× 87 1.0k
T Tomoyoshi Japan 15 196 0.3× 112 0.2× 73 0.2× 117 0.4× 70 0.3× 137 760
P. R. Riddle United Kingdom 17 268 0.4× 107 0.2× 89 0.2× 168 0.6× 20 0.1× 28 927
Salvatore Saitta Italy 22 85 0.1× 259 0.5× 75 0.2× 165 0.6× 75 0.3× 50 1.1k
S. Jacobs United States 23 298 0.5× 109 0.2× 193 0.4× 152 0.6× 24 0.1× 46 1.3k
Sang Eun Lee South Korea 17 79 0.1× 64 0.1× 67 0.2× 257 1.0× 45 0.2× 47 1.0k
S. Goralnick United States 9 129 0.2× 94 0.2× 50 0.1× 83 0.3× 55 0.2× 13 563
Laura O’Connor United States 9 179 0.3× 84 0.2× 38 0.1× 202 0.8× 39 0.2× 19 631
Soheir Mahfouz Egypt 13 44 0.1× 59 0.1× 79 0.2× 180 0.7× 38 0.2× 24 774

Countries citing papers authored by John Bolodeoku

Since Specialization
Citations

This map shows the geographic impact of John Bolodeoku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Bolodeoku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Bolodeoku more than expected).

Fields of papers citing papers by John Bolodeoku

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Bolodeoku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Bolodeoku. The network helps show where John Bolodeoku may publish in the future.

Co-authorship network of co-authors of John Bolodeoku

This figure shows the co-authorship network connecting the top 25 collaborators of John Bolodeoku. A scholar is included among the top collaborators of John Bolodeoku based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Bolodeoku. John Bolodeoku is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bolodeoku, John, et al.. (2025). Thyroglobulin as an adjunct biomarker for assessing thyroid function during pregnancy. Qatar medical journal. 2025(3). 82–82.
2.
3.
Bolodeoku, John, et al.. (2019). Quantitative Point of Care testing of HCG in early pregnancy units: A Review. 2(2). 2 indexed citations
4.
Bolodeoku, John. (2017). Self-monitoring blood cholesterol (SMBC) testing: within-person day to day variation in a healthy volunteer. Medical Research Archives. 5(9). 1 indexed citations
5.
Bolodeoku, John, et al.. (2017). Laboratory Tests Turnaround Time in Outpatient and Emergency Patients in Nigeria: Results of A Physician Survey on Point of Care Testing. International Journal of Medical Research & Health Sciences. 6(5). 76–81. 4 indexed citations
6.
Wesnes, Keith, Chris J. Edgar, Reiner Tretter, & John Bolodeoku. (2009). Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opinion on Drug Safety. 8(6). 615–626. 67 indexed citations
7.
Cardozo, Linda, Ted Drogendijk, & John Bolodeoku. (2008). The efficacy of solifenacin 5/10mg on ‘urgency’ endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study. 2 indexed citations
8.
Cardozo, Linda, Rodolfo Milani, Pedro Arañó, et al.. (2008). Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial. British Journal of Urology. 102(9). 1120–1127. 111 indexed citations
9.
Chapple, Christopher R., Ted Drogendijk, D.M. Wright, & John Bolodeoku. (2007). POS-01.134: Responses to solifenacin in patients >65 years and ≤65 years with overactive bladder syndrome: post-hoc results from the randomised, double-blind STAR study. Urology. 70(3). 232–232. 3 indexed citations
10.
Chapple, Christopher R., Vik Khullar, Roberto Mario Scarpa, et al.. (2007). Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg. European Urology. 52(4). 1195–1203. 61 indexed citations
11.
12.
Chapple, Christopher R., et al.. (2006). Comparison of solifenacin 5 MG and tolterodine ER 4 mg in the star OAB study.. Neurourology and Urodynamics. 25(6). 617–617. 1 indexed citations
13.
Chapple, Christopher R., R. Martínez-García, Luigi Selvaggi, et al.. (2005). A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial. European Urology. 48(3). 464–470. 246 indexed citations
14.
Bolodeoku, John. (2003). PCR Analysis of CD44 Variants in Tumors. Humana Press eBooks. 16. 189–202.
15.
Randeva, HS, et al.. (1999). ELEVATED SERUM CREATINE KINASE ACTIVITY IN A PATIENT WITH ACUTE PANCREATITIS. International Journal of Clinical Practice. 53(6). 482–483. 4 indexed citations
16.
Yoshida, Kazuhiro, Takashi Sugino, Hidetoshi Tahara, et al.. (1997). Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer. 79(2). 362–369. 177 indexed citations
17.
Olukoga, A O, John Bolodeoku, & D. Donaldson. (1997). Cerebrospinal fluid analysis in clinical diagnosis.. Journal of Clinical Pathology. 50(3). 187–192. 6 indexed citations
18.
Sugino, Takashi, Kazuhiro Yoshida, John Bolodeoku, David G. Jackson, & Steve Goodison. (1997). Telomerase activity and its inhibition in benign and malignant breast lesions. The Journal of Pathology. 183(1). 57–61. 22 indexed citations
19.
Gorham, Hazel C., et al.. (1996). Distribution of CD44 messenger RNA in archival paraffin wax embedded tumours and normal tissues viewed by in situ hybridisation. Molecular Pathology. 49(3). M147–M150. 4 indexed citations
20.
Sugino, Takashi, Kazuhiro Yoshida, John Bolodeoku, et al.. (1996). Telomerase activity in human breast cancer and benign breast lesions: Diagnostic applications in clinical specimens, including fine needle aspirates. International Journal of Cancer. 69(4). 301–306. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Travis J. Jerde Breakdown of academic impact, for papers by Ying-hao SUN Breakdown of academic impact, for papers by T Tomoyoshi Breakdown of academic impact, for papers by P. R. Riddle Breakdown of academic impact, for papers by Salvatore Saitta Breakdown of academic impact, for papers by S. Jacobs Breakdown of academic impact, for papers by Sang Eun Lee Breakdown of academic impact, for papers by S. Goralnick Breakdown of academic impact, for papers by Laura O’Connor Breakdown of academic impact, for papers by Soheir Mahfouz
Rankless by CCL
2026